JANSSEN Autonomy 63733657ALZ2002 (Phase 2)

Back to Drug Development Trials
Drug Development Trials

About the trial

A phase 2 safety study to evaluate the efficacy and safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in participants with mild cognitive impairment and early Alzheimer’s disease.

The drug is administrated by monthly infusion and is proposed to prevent tau collection in the brain, a known hallmark of AD.